TY  - JOUR
AU  - Michael, Fossel
AU  - Pang, Bo
AU  - Le Gal, Solène
PY  - 2017
DA  - 2017/03/14
TI  - Perspectives on the Neurobiology of Antipsychotic Drugs in  Psychiatric Disorders
JO  - OBM Neurobiology
SP  - 001
VL  - 01
IS  - 01
AB  - Antipsychotics have been a pillar in the treatment of schizophrenia since their introduction more than 60 years ago. Their variety in structures and receptor binding properties confers on them a complex clinical profile of effectiveness and risk of adverse side-effects. Although antipsychotics are best known for their therapeutic effects in schizophrenia, these are limited to the positive symptoms, with much less influence on negative symptoms or cognitive deficits. Moreover, although the newer (so-called second-generation) antipsychotics were thought to have superior clinical profiles, this opinion has been undermined by most recent large-scale studies and meta-analyses. In fact, the beneficial effects of all antipsychotic drugs in the treatment of schizophrenia are remarkably similar, with the possible exception of clozapine. However, some evidence suggests differences in the side-effect profiles between the first- and second-generation drugs. Moreover, several of the second-generation antipsychotics are now also approved for several other conditions, such as bipolar disorder and autism spectrum disorders. In this review, we discuss the clinical usefulness of antipsychotics, their possible mode of action and describe the limitations of their use.
SN  - 2573-4407
UR  - https://doi.org/10.21926/obm.neurobiol.1701001
DO  - 10.21926/obm.neurobiol.1701001
ID  - Michael2017
ER  -